Skip to contentB
Biogen Inc.
B
BIIBBiogen Inc. Q1 2020 · 10-Q
Revenue$3.53B$3.53B+1.3% vs Q1 2019 Net Income$1.40B$1.40B−0.7% vs Q1 2019 EPS Diluted$8.08$8.08+13.0% vs Q1 2019 Gross Profit$3,080,000,000+6.7% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Biogen Inc. · CIK 875045 · Engraved from SEC EDGAR
Operating Cash Flow$1,467,300,000+0.5% Free Cash Flowderived$1,317,600,000−1.1% Margins · derivedGross margin87.1%+4.4 pt vs Q1 2019
Operating margin51.5%+8.4 pt vs Q1 2019
Net margin39.6%−0.8 pt vs Q1 2019
ended Mar 31, 2020 · filed Apr 23, 2020 · 23 d after period end